Pyxis Oncology Management
Management criteria checks 2/4
Pyxis Oncology's CEO is Lara Sullivan, appointed in Dec 2019, has a tenure of 4.42 years. total yearly compensation is $4.44M, comprised of 14.1% salary and 85.9% bonuses, including company stock and options. directly owns 3.17% of the company’s shares, worth $8.18M. The average tenure of the management team and the board of directors is 2.3 years and 2.7 years respectively.
Key information
Lara Sullivan
Chief executive officer
US$4.4m
Total compensation
| CEO salary percentage | 14.1% |
| CEO tenure | 4.4yrs |
| CEO ownership | 3.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait
Mar 28Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis
Jan 18Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?
Feb 18
Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation
Sep 01Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06
Aug 15We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely
Apr 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$4m | US$625k | -US$74m |
| Sep 30 2023 | n/a | n/a | -US$94m |
| Jun 30 2023 | n/a | n/a | -US$99m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$5m | US$565k | -US$121m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$88m |
| Mar 31 2022 | n/a | n/a | -US$71m |
| Dec 31 2021 | US$17m | US$565k | -US$76m |
| Sep 30 2021 | n/a | n/a | -US$64m |
| Jun 30 2021 | n/a | n/a | -US$53m |
| Mar 31 2021 | n/a | n/a | -US$47m |
| Dec 31 2020 | US$555k | US$375k | -US$13m |
Compensation vs Market: Lara's total compensation ($USD4.44M) is above average for companies of similar size in the US market ($USD1.59M).
Compensation vs Earnings: Lara's compensation has been consistent with company performance over the past year.
CEO
Lara Sullivan
4.4yrs
Tenure
US$4,442,501
Compensation
Dr. Lara S. Sullivan, M.D., MBA, has been Chief Executive Officer, President and Director at Pyxis Oncology, Inc. since December 2019. She was a Principal at Paul Capital Partners, since April 2007. Dr. Su...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.4yrs | US$4.44m | 3.17% $ 8.2m | |
| CFO & COO | 2.8yrs | US$1.82m | 1.06% $ 2.7m | |
| Chief Medical Officer | less than a year | US$1.13m | no data | |
| Chief Accounting Officer | 2.8yrs | no data | 0.26% $ 678.8k | |
| Interim Chief Technology Officer | 2.3yrs | no data | no data | |
| Chief Scientific Officer | 2.1yrs | no data | no data | |
| Senior Vice President of Portfolio & Program Management | 2.3yrs | no data | no data |
2.3yrs
Average Tenure
61yo
Average Age
Experienced Management: PYXS's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 4.4yrs | US$4.44m | 3.17% $ 8.2m | |
| Independent Chairman | 5yrs | US$395.48k | 0.64% $ 1.7m | |
| Member of Clinical & Translational Medicine Advisory Board | 2.9yrs | no data | no data | |
| Independent Director | 2.7yrs | US$341.98k | 0.35% $ 903.1k | |
| Independent Director | 2.7yrs | US$357.48k | 0.37% $ 946.9k | |
| Independent Director | 2.7yrs | US$360.48k | 0.14% $ 361.5k | |
| Member of Clinical & Translational Medicine Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | 2.1yrs | no data | no data | |
| Chairperson of Technical Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | no data | no data | no data | |
| Member of Technical Advisory Board | no data | no data | no data |
2.7yrs
Average Tenure
54yo
Average Age
Experienced Board: PYXS's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.